A third type of mouse A chain was identified in the course of examining light chains from four myeloma proteins and two monoclonal antibodies. On the basis of their antigenic properties and a characteristic COOH-terminal tryptic peptide, the light chains from these immunoglobulins had previously been provisionally identified as A2 chains. However, four of these chains, designated now as A3 (or We first recognized A3 chains through a chance observation in the course of evaluating the difference in amino acid sequence between L315 (the prototype A2 chain) and the sequence encoded by the germ-line gene for the A2 variable region (7). For this evaluation we examined six chains that had previously been provisionally identified as A2 chains (unpublished data). When the fragments produced by cleaving the chains with CNBr were analyzed we found that four ofthem, the A3 were then alkylated with iodoacetamide and subjected to gel filtration on Sephadex G-100 in 6 M urea/i M acetic acid to separate heavy and light chains (10). To separate the A chains from contaminating K chains, the pooled light chains were subjected to gel filtration on Sephadex G-75 in 0.15 M NaCVK phosphate, pH 7.2 (PJNaCl). Under these conditions, A chains form noncovalently associated dimers whereas most K chains do not (11,12). The removal of K contaminants was especially important with light chains from the monoclonal (hybridoma) antibodies because many of these molecules had both A and K chains; the latter were derived from the fused myeloma NS-1 cells. Extensive reduction of the purified A chains (to cleave intrachain disulfide bridges) was usually carried out with 0.01 M dithiothreitoV6 M guanidine.HCV0.2 M Tris-HCl, pH 7.6, followed by alkylation with 4-vinylpyridine (13). Chemical Modifications. Cleavage of reduced or unreduced light chains at methionyl residues was carried out in 70% formic acid with a 150-fold molar excess of CNBr (with respect to methionine) at room temperature for 24 hr. Reaction with citraconic anhydride was -carried out as described (14) and the same method was used for succinylation. The procedure for treatment with hydroxylamine was as described (15). Ethyleneimine (ICN Pharmaceuticals, Plainview, NJ) was used as described (4)